SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Farrell MA, Vinters HV. General neuropathology of epilepsy. In: EngelJJr, PedleyTA, eds. Epilepsy: a comprehensive textbook. Philadelphia : Lippincott-Raven, 1997: 15774.
  • 2
    Aronica E, Leenstra S, Van Veelen CW, et al. Glioneuronal tumors and medically intractable epilepsy: a clinical study with long-term follow-up of seizure outcome after surgery. Epilepsy Res 2001;43: 17991.
  • 3
    Blumcke I, Wiestler OD. Gangliogliomas: an intriguing tumor entity associated with focal epilepsies. J Neuropathol Exp Neurol 2002;61: 57584.
  • 4
    Wolf HK, Birkholz T, Wellmer J, et al. Neurochemical profile of glioneuronal lesions from patients with pharmacoresistant focal epilepsies. J Neuropathol Exp Neurol 1995;54: 68997.
  • 5
    Aronica E, Gorter JA, Jansen GH, et al. Expression of connexin 43 and connexin 32 gap-junction proteins in epilepsy-associated brain tumors and in the perilesional epileptic cortex. Acta Neuropathol (Berl) 2001;101: 44959.
  • 6
    Aronica E, Yankaya B, Jansen GH, et al. Ionotropic and metabotropic glutamate receptor protein expression in glioneuronal tumours from patients with intractable epilepsy. Neuropathol Appl Neurobiol 2001;27: 22337.
  • 7
    Prayson RA, Estes ML, Morris HH. Coexistence of neoplasia and cortical dysplasia in patients presenting with seizures. Epilepsia 1993;34: 60915.
  • 8
    Blumcke IM, Lobach HK, Wolf HK, et al. Evidence for developmental precursor lesions in epilepsy-associated glioneuronal tumors. Microsc Res Tech 1999;46: 538.
  • 9
    Becker AJ, Klein H, Baden T, et al. Mutational and expression analysis of the reelin pathway components CDK5 and doublecortin in gangliogliomas. Acta Neuropathol 2002;104: 4038.
  • 10
    Khajavi K, Comair YG, Prayson RA, et al. Childhood ganglioglioma and medically intractable epilepsy: a clinicopathological study of 15 patients and a review of the literature. Pediatr Neurosurg 1995;22: 1818.
  • 11
    Mathern GW, Giza CC, Yudovin S, et al. Postoperative seizure control and antiepileptic drug use in pediatric epilepsy surgery patients: the UCLA experience, 1986–1997. Epilepsia 1999;40: 17409.
  • 12
    Morris HH, Matkovic Z, Estes ML, et al. Ganglioglioma and intractable epilepsy: clinical and neurophysiologic features and predictors of outcome after surgery. Epilepsia 1998;39: 30713.
  • 13
    Scheffer GL, Scheper RJ. Drug resistance molecules: lessons from oncology. Novartis Foundation Symposium 2002;243: 1931; discussion 31–7.
  • 14
    Loscher W, Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther 2002;301: 714.
  • 15
    Sun H, Dai H, Shaik N, et al. Drug efflux transporters in the CNS. Adv Drug Deliv Rev 2003;55: 83105.
  • 16
    Sisodiya SM, Lin WR, Harding BN, et al. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 2002;125: 2231.
  • 17
    Aronica E, Gorter JA, Jansen GH, et al. Expression and cellular distribution of multidrug transporter proteins in two major causes of medically intractable epilepsy: focal cortical dysplasia and glioneuronal tumors. Neuroscience 2003;118: 41729.
  • 18
    Kedersha NL, Rome LH. Isolation and characterization of a novel ribonucleoprotein particle: large structures contain a single species of small RNA. J Cell Biol 1986;103: 699709.
  • 19
    Scheffer GL, Flens MJ Giaccone G, et al. Major vault protein LRP-related multidrug resistance. Am J Pathol 1996;148: 87787.
  • 20
    Kedersha NL, Rome LH. Vaults, II: ribonucleoprotein structures are highly conserved among higher and lower eukaryotes. J Neurosci 1991;11: 25668.
  • 21
    Izquierdo MA, Scheffer GL. Flens MJ, et al. Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. Am J Pathol 1996;148: 87787.
  • 22
    Scheffer GL, Schroeijers AB, Izquierdo MA, et al. Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer. Curr Opin Oncol 2000;12: 5506.
  • 23
    Chugani DC, Rome LH, Kedersha NL. Evidence that vault ribonucleoprotein particles localize to the nuclear pore complex. J Cell Sci 1993;106: 239.
  • 24
    Rome LN, Kedersha, Chugani D. Unlocking vaults: organelles in search of a function. Trends Cell Biol 1991;1: 4750.
  • 25
    Hamill DR, Suprenant KA. Characterization of the sea urchin major vault protein: a possible role for vault ribonucleoprotein particles in nucleocytoplasmic transport. Dev Biol 1997;190: 11728.
  • 26
    Abbondanza CV, Rossi A, Roscigno C, et al. Interaction of vault particles with estrogen receptor in the MCF-7 breast cancer cell. J Cell Biol 1998;141: 130110.
  • 27
    Kong LB, Siva AC, Rome LH, et al. Structure of the vault, a ubiquitous cellular component: review: resolution issues in single-particle reconstruction. Structure 1999;7: 3719.
  • 28
    Kickhoefer VA, Rajavel KS, Scheffer GL, et al. Vaults are up-regulated in multidrug-resistant cancer cell lines. J Biol Chem 1998;273: 89714.
  • 29
    Schroeijers AB, Scheffer GL, Reurs AW, et al. Detection of the Mr 110,000 lung resistance-related protein LRP/MVP with monoclonal antibodies. J Histochem Cytochem 2001;49: 137985.
  • 30
    Berger W, Spiegl-Kreinecker S, Buchroithner J, et al. Overexpression of the human major vault protein in astrocytic brain tumor cells. Int J Cancer 2001;94: 37782.
  • 31
    Raidl M, Berger W, Schulte-Hermann R, et al. Expression of the lung resistance-related protein in human and rat hepatocarcinogenesis. Am J Physiol Gastrointest Liver Physiol 2002;283: G111724.
  • 32
    Hu Y, Stephen AG, Cao J, et al. A very early induction of major vault protein accompanied by increased drug resistance in U-937 cells. Int J Cancer 2002;97: 14956.
  • 33
    Mossink MH, Van Zon A, Franzel-Luiten E, et al. Disruption of the murine major vault protein (MVP/LRP) gene does not induce hypersensitivity to cytostatics. Cancer Res 2002;62: 7298304.
  • 34
    Schroeijers AB, Reurs AW, Scheffer GL, et al. Up-regulation of drug resistance-related vaults during dendritic cell development. J Immunol 2002;168: 15728.
  • 35
    KleihuesP, CavaneeWK, eds. World Health Organization classification of tumours: pathology and genetics of tumours of the nervous system. Lyon : IARC Press, 2000.
  • 36
    Van Veelen CW, Debets RM, Van Huffelen AC, et al. Combined use of subdural and intracerebral electrodes in preoperative evaluation of epilepsy. Neurosurgery 1990;26: 93101.
  • 37
    Engel JJ. Outcome with respect to epileptic seizures. In: EngelJJr, ed. Surgical treatment of epilepsies. New York : Raven Press, 1987: 55371.
  • 38
    Khurgel M, Ivy GO. Astrocytes in kindling: relevance to epileptogenesis. Epilepsy Res 1996;26: 16375.
  • 39
    Aronica E, Van Vliet EA, Mayboroda OA, et al. Upregulation of metabotropic glutamate receptor subtype mGluR3 and mGluR5 in reactive astrocytes in a rat model of mesial temporal lobe epilepsy. Eur J Neurosci 2000;12: 233344.
  • 40
    Schroeijers AB, Scheffer GL, Flens MJ, et al. Immunohistochemical detection of the human major vault protein LRP with two monoclonal antibodies in formalin-fixed, paraffin-embedded tissues. Am J Pathol 1998;152: 738.
  • 41
    Scheffer GL, Pijnenborg AC, Smit EF, et al. Multidrug resistance related molecules in human and murine lung. J Clin Pathol 2002;55: 3329.
  • 42
    Berger WL, Elbling M, Micksche M. Expression of the major vault protein LRP in human non-small-cell lung cancer cells: activation by short-term exposure to antineoplastic drugs. Int J Cancer 2000;88: 293300.
  • 43
    Smith PK, Krohn RI, Hermanson GT, et al. Measurement of protein using bicinchoninic acid (published erratum appears in Anal Biochem 1987;163:279). Anal Biochem 1985;150: 7685.
  • 44
    Romijn HJ, Van Uum JF, Breedijk I, et al. Double immunolabeling of neuropeptides in the human hypothalamus as analyzed by confocal laser scanning fluorescence microscopy. J Histochem Cytochem 1999;47: 22936.
  • 45
    Vandeputte DA, Troost D, Leenstra S, et al. Expression and distribution of id helix-loop-helix proteins in human astrocytic tumors. Glia 2002;38: 32938.
  • 46
    Kedersha NL, Rome LH. Vaults: large cytoplasmic RNPs that associate with cytoskeletal elements. Mol Biol Rep 1990;14: 1212.
  • 47
    Flens MJ, Scheffer GL, Van Der Valk P, et al. Identification of novel drug resistance-associated proteins by a panel of rat monoclonal antibodies. Int J Cancer 1997;73: 24957.
  • 48
    Sisodiya SM. Mechanisms of antiepileptic drug resistance. Curr Opin Neurol 2003;16: 197201.
  • 49
    Sugawara I, Akiyama S, Scheper RJ, et al. Lung resistance protein (LRP) expression in human normal tissues in comparison with that of MDR1 and MRP. Cancer Lett 1997;112: 2331.
  • 50
    Chugani DC, Kedersha NL, Rome LH. Vault immunofluorescence in the brain: new insights regarding the origin of microglia. J Neurosci 1991;11: 25668.
  • 51
    Duggal N, Hammond RR. Nestin expression in ganglioglioma. Exp Neurol 2002;174: 8995.
  • 52
    Blumcke I, Lobach M, Wolf HK, et al. Evidence for developmental precursor lesions in epilepsy-associated glioneuronal tumors. Microsc Res Tech 1999;46: 538.
  • 53
    Tews DS, Nissen A, Kulgen C, et al. Drug resistance-associated factors in primary and secondary glioblastomas and their precursor tumors. J Neurooncol 2000;50: 22737.
  • 54
    Morikawa S, Baluk P, Kaidoh T, et al. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 2002;160: 9851000.
  • 55
    Cendes F, Watson C, Andermann F, et al. Frequency and characteristics of dual pathology in patients with lesional epilepsy. Neurology 1997;48: 43744.
  • 56
    Bocti C, Robitaille Y, Diadori P, et al. The pathological basis of temporal lobe epilepsy in childhood. Neurology 2003;60: 1915.
  • 57
    Thom M, D'Arrigo C, Scaravilli F. Hippocampal sclerosis with hypertrophy of end folium pyramidal cells. Acta Neuropathol 1999;98: 10710.